Samsara BioCapital

Dr. Srinivas Akkaraju, the Founder and Managing General Partner, leads investment decisions. He is supported by partners Mike Dybbs and Abe Bassan, and a deep bench of venture partners — including former CFOs and R&D heads from BioMarin, Genentech, and other biopharma companies — who contribute to due diligence and portfolio-company oversight.

The firm targets the full biotech lifecycle: seed-stage company creation, early-stage venture rounds, expansion and late-stage financings, and public-company positions. Its portfolio includes recent IPOs such as Arcellx and Prime Medicine, as well as preclinical and clinical-stage private companies such as Kalaris Therapeutics and Tentarix Biotherapeutics.

Samsara does not publish a formal exclusion list. Its portfolio is concentrated almost entirely on human therapeutics — spanning oncology, immunology, cardiometabolic, gene therapy, and ophthalmology — with limited exposure to diagnostics and digital health. Non-therapeutic sectors such as medical devices or healthcare IT appear absent from the disclosed portfolio.